|
|
|
| Analysis of one case misdiagnosed of moderately differentiated adenocarcinoma in the left inferior lobe of the Lung |
| GUO Yang1 JIA Huijun2 YAO Jie1 DONG Bo3 YANG Feng1 LIU Fang1 LI Xiaowei1 LIU Deyu3 |
1.Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712046, China;
2.Fugu County Traditional Chinese Medicine Hospital, Shaanxi Province, Yulin 719400, China;
3.Department of Orthopedics, Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712000, China |
|
|
|
Abstract Lung cancer is a malignant tumor with the highest incidence and mortality in the world. Its onset is insidious, early signs and symptoms are subtle, clinical misdiagnosis and missed diagnosis often occur, delaying the best time for treatment. In this paper, a case with the first symptom of left shoulder joint pain was misdiagnosed as ischemic necrosis of left humerus head. Combined with relevant literatures at home and abroad, this disease was introduced in terms of its pathogenesis, imaging characteristics, pathological tissue characteristics and the differentiation of similar diseases. The patient was admitted to Affiliated Hospital of Shaanxi University of Chinese Medicine on May 30, 2019 due to “left shoulder pain with limited movement for one week”. The patient was considered as tumor lesions, peripheral lung cancer with possibility of multiple metastasis in the lungs. The postoperative pathology examination showed differentiatiated carcinoma in the left lower lobe. The first onset symptoms of the patient do not match the symptoms of lung cancer. The doctor diagnozed and treated the patient with a fixed thinking mode while failing to diverge thinking, effectively differentiate the symptoms. The related imaging signs are not typical, leading to misdiagnosis. The purpose of this paper is to analyzed and summarized the case and provide reference for improving the diagnosis and treatment of lung cancer in the future.
|
|
|
|
|
|
[1] Siegel RL，Miller KD，Jemal A. Cancer statistics [J]. CA Cancer J Clin，2019，65（1）：5-29.
[2] 胡波，王道义.血小板和血浆纤维蛋白原水平与非小细胞肺癌转移及进展的相关研究[J].国际检验医学杂志，2015，36（2）：200-202.
[3] 张树才，张卉.《中国原发性肺癌诊疗规范（2015版）》内科治疗解析[J].中华医学信息导报，2015，30（8）：19.
[4] 赵诤，李海军，陈效琴，等.晚期非小细胞肺癌患者TKI靶向治疗与肿瘤组织EGFR基因突变的关系[J].中国医药导报，2019，16（10）：162-165.
[5] 迟文成，王彬彬，杨帆，等.针药联合治疗非小细胞肺癌患者化疗后癌因性失眠的临床效果[J].中国医药导报，2019，16（23）：114-117.
[6] Zhou ES，Partridge AH，Syrjala KL，et al. Evaluation and treatment of insomnia in adult cancer survivorship programs [J]. J Cancer Surviv，2017，11（1）：74-79.
[7] Induru RR，Walsh D. Cancer-related insomnia [J]. Am J Hosp Palliat Care，2014，31（7）：777-785.
[8] 陈冬娜，马玉洁，刘娜，等.培美曲塞长期维持治疗晚期肺腺癌的疗效与安全性分析[J].癌症进展，2019，17（16）：1911-1915.
[9] Lortet-Tieulent J，Soerjomataram I，Ferlay J，et al. International trends in lung cancer incidence by histological subtype：adenocarcinoma stabilizing in men but still increasing in women [J]. Lung Cancer，2014，84（1）：13-22.
[10] 曹仲年，郑容，魏正茂，等.肿瘤标志物和肺门淋巴结与肺腺癌全身骨显像骨转移的关系[J].肿瘤防治研究，2019， 46（2）：149-152.
[11] 孙燕，管忠震，廖美琳，等.肺癌骨转移诊疗专家共识（2014版）[J].中国肺癌杂志，2014，17（2）：57-72.
[12] 张清.内外科护理学[M].5版.北京：清华大学出版社，2010：9.
[13] 陈静，段凤英.血清肿瘤标志物检测在肺癌中的临床应用价值[J].南昌大学学报：医学版，2014，54（3）：92-95.
[14] 王颖颖，赵静.探讨肺癌肿瘤标志物联合检测在诊断中的意义[J].实验与检验医学，2016，34（5）：639-642.
[15] 张凌.血清肺癌标志物研究现状及进展[J].实用医学临床杂志，2014，11（6）：198-200.
[16] Del Rivero J，Enewold L，Thomas A． Metastatic lung cancer in the age of targeted therapy：improving long-term survival [J]. Transl Lung Cancer Res，2016，5（6）：727-730.
[17] 刘璐瑶，刘可可，张雯雯，等.肿瘤相关巨噬细胞分泌的细胞因子在肿瘤微环境中作用的研究进展[J].中国医药导报，2019，16（11）：30-33.
[18] Wang YY，Zhao J. Clinical significance of combined detection of tumor markers in lung cancer [J]. Shi Yan Yu Jian Yan Yi Xue，2016，34（5）：639.
[19] 朱自力，朱海霞，张福明，等.肺癌患者血清肿瘤标志物水平与骨转移的关系[J].江苏医药，2011，37（8）：943-945.
[20] Wu YL，Saijo N，Thongprasert S，et al. Efficacy according to blind independent central review：post-hoc analyses from the phase Ⅲ，randomized，multicenter，IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFＲ mutation-positive advanced NSCLC [J]. Lung Cancer，2017，104：119-125. |
|
|
|
